NICE approves radium-223 for prostate cancer


More patients in England and Wales with prostate cancer can now receive radium-233 following NICE approval for routine NHS use.

NICE previously recommended the treatment for patients who have had initial treatment with docetaxel, while those without previous docetaxel treatment had to access the drug through the Cancer Drugs Fund (CDF).Radium-233 is offered to prostate cancer patients whose disease has spread to the bone.

Radium-233 is offered to prostate cancer patients whose disease has spread to the bone.

Source: NICE

 

Please follow and like us: